Thomas Jefferson hospital intends to introduce the system for testing acute myeloid leukemia (AML) in this fall.

The combination of karyotype analysis, fluorescence in situ hybridization (FISH) and the evaluation of mutational status of molecular markers by next generation sequencing (NGS) will help to improve strategies for risk stratification and targeted therapy.

According to the firm, the results of these disparate tests were reported separately, traditionally.

GenomOncology is expanding its GO Clinical Workbench platform to enable independent and cumulative analysis and reporting of these assays, to improve the situation.

Jefferson’s molecular pathology team headed by Dr Stephen Peiper is testing the new system and guiding its development from the clinical perspective.

Dr. Peiper said: "For many diseases we deal with at Jefferson, the best results are obtained by applying multiple analytical techniques.

"This is especially true for AML, for which karyotype analysis, fluorescence in situ hybridization, and next generation DNA sequencing provide complementary information."

The two groups will showcase the initial results of the collaboration at two scientific meetings, including the Individualizing Medicine Conference that is being held from 20 to 25 September and the annual meeting of the American Society of Human Genetics, which will be held from 6 to 10 October.